MCID: CRB037
MIFTS: 68

Cerebral Palsy

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Cerebral Palsy

MalaCards integrated aliases for Cerebral Palsy:

Name: Cerebral Palsy 12 74 52 53 29 54 6 42 3 15 37 17 71 32
Infantile Cerebral Palsy 12 71
Cerebral Palsy, Mixed 71
Mixed Cerebral Palsy 52
Palsy, Cerebral 39
Palsy Cerebral 74

Classifications:



External Ids:

Disease Ontology 12 DOID:1969
MeSH 43 D002547
NCIt 49 C34460
SNOMED-CT 67 1178005
ICD10 32 G80 G80.9
UMLS 71 C0007789 C0392549 C0751024

Summaries for Cerebral Palsy

NINDS : 53 The term cerebral palsy refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement, muscle coordination, and balance. CP affects the part of the brain that controls muscle movements.  The majority of children with cerebral palsy are born with it, although it may not be detected until months or years later. The early signs of cerebral palsy usually appear before a child reaches 3 years of age. The most common are a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a “scissored” gait; and muscle tone that is either too stiff or too floppy. Other neurological symptoms that commonly occur in individuals with CP include seizures, hearing loss and impaired vision, bladder and bowel control issues, and pain and abnormal sensations. A small number of children have CP as the result of brain damage in the first few months or years of life, brain infections such as bacterial meningitis or viral encephalitis, or head injury from a motor vehicle accident, a fall, or child abuse. The disorder isn't progressive, meaning that the brain damage typically doesn't get worse over time. Risk factors associated with CP do not cause the disorder but can increase a child's chance of being born with the disorder.CP is not hereditary.

MalaCards based summary : Cerebral Palsy, also known as infantile cerebral palsy, is related to spastic cerebral palsy and inherited congenital spastic tetraplegia, and has symptoms including seizures, tremor and dystonia. An important gene associated with Cerebral Palsy is ADD3 (Adducin 3), and among its related pathways/superpathways are Allograft rejection and Measles. The drugs Levodopa and Heparin have been mentioned in the context of this disorder. Affiliated tissues include Blood and Umbilical Cord, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A brain disease that is caused by damage to the motor control centers of the developing brain during pregnancy, during childbirth or after birth, which affects muscle movement and balance.

NIH Rare Diseases : 52 Cerebral palsy refers to a group of neurological disorders that can affect the brain and/or spinal cord. Signs and symptoms generally appear during infancy or early childhood and vary based on the type of cerebral palsy (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy), the severity of the condition and which area(s) of the brain are affected. Common features include a lack of muscle coordination when performing voluntary movements (ataxia ); stiff or tight muscles and exaggerated reflexes (spasticity ); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a "scissored" gait; and muscle tone that is either too stiff or too floppy. Cerebral palsy is caused by abnormal brain development or damage to the developing brain. Most of these problems occur as the baby grows in the womb; however, they can happen at any time during the first 2 years of life. There is no cure for cerebral palsy, but treatment is available to alleviate some symptoms. This may include physical, occupational, and speech therapy; certain medications; surgery; and/or devices (i.e. braces, wheelchairs) to aid in mobility.

MedlinePlus : 42 Cerebral palsy is a group of disorders that affect a person's ability to move and to maintain balance and posture. The disorders appear in the first few years of life. Usually they do not get worse over time. People with cerebral palsy may have difficulty walking. They may also have trouble with tasks such as writing or using scissors. Some have other medical conditions, including seizure disorders or mental impairment. Cerebral palsy happens when the areas of the brain that control movement and posture do not develop correctly or get damaged. Early signs of cerebral palsy usually appear before 3 years of age. Babies with cerebral palsy are often slow to roll over, sit, crawl, smile, or walk. Some babies are born with cerebral palsy; others get it after they are born. There is no cure for cerebral palsy, but treatment can improve the lives of those who have it. Treatment includes medicines, braces, and physical, occupational and speech therapy. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Cerebral palsy (CP) is a group of disorders that affect a person's ability to move and maintain balance and posture. CP is the most common motor disability in childhood. CDC estimates that an average of 1 in 323 children in the U.S. have CP.

Wikipedia : 74 Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Signs and... more...

Related Diseases for Cerebral Palsy

Diseases related to Cerebral Palsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 996)
# Related Disease Score Top Affiliating Genes
1 spastic cerebral palsy 35.1 PLP1 KANK1 GAD1
2 inherited congenital spastic tetraplegia 33.8 KANK1 GAD1 ADD3
3 spastic paraplegia 52, autosomal recessive 33.7 AP4S1 AP4M1 AP4E1 AP4B1
4 spastic paraplegia 47, autosomal recessive 33.7 AP4S1 AP4M1 AP4E1 AP4B1
5 spastic paraplegia 51, autosomal recessive 33.6 AP4S1 AP4M1 AP4E1 AP4B1
6 spastic paraplegia 50, autosomal recessive 33.6 AP4S1 AP4M1 AP4E1 AP4B1
7 hypertonia 33.3 AP4S1 AP4M1 AP4B1
8 hereditary spastic paraplegia 33.1 PLP1 GAD1 AP4S1 AP4M1 AP4E1 AP4B1
9 neonatal jaundice 33.1 TNF IL6 IL1B
10 hereditary spastic paraplegia 51 32.8 AP4S1 AP4M1 AP4E1 AP4B1
11 quadriplegia 32.6 PLP1 KANK1 AP4S1 AP4M1 AP4E1 AP4B1
12 paraplegia 32.1 PLP1 AP4S1 AP4M1 AP4E1 AP4B1
13 brain injury 31.5 IL6 BDNF APOE
14 gastroesophageal reflux 31.4 TNF IL6 IL1B CXCL8
15 eclampsia 31.3 TNF NOS3 MTHFR
16 traumatic brain injury 31.3 IL6 BDNF APOE
17 sleep disorder 31.2 TNF IL6 BDNF
18 spinal cord injury 31.2 TNF IL6 CXCL8 BDNF
19 hydrocephalus 31.1 TNF TLR4 MTHFR BDNF APOE
20 acute cystitis 31.1 TNF TLR4 IL6 CXCL8
21 chorioamnionitis 31.0 TNF TLR4 MMP8 IL6 IL1B CXCL8
22 pre-eclampsia 30.9 TNF TLR4 NOS3 MTHFR IL6 IL1B
23 disease of mental health 30.9 TNF IL6 GAD1 BDNF APOE
24 autism 30.9 TNF MTHFR IL1B GAD1 BDNF AUTS2
25 cerebrovascular disease 30.9 TNF TLR4 MTHFR IL6 APOE
26 rubella 30.9 TNF TLR4 IL6
27 encephalomalacia 30.8 TLR4 MTHFR IL6 IL1B BDNF
28 funisitis 30.7 MMP8 IL6 IL1B CXCL8
29 osteoarthritis 30.7 TNF IL6 IL1B CXCL8
30 focal epilepsy 30.7 IL6 IL1B GAD1 BDNF
31 gingivitis 30.7 TNF MMP8 IL6 IL1B CXCL8
32 toxoplasmosis 30.7 TNF TLR4 IL6 IL1B
33 exanthem 30.7 TNF IL6 CXCL8
34 cytomegalovirus infection 30.7 TNF IL6 IL1B CXCL8
35 ap-4-associated hereditary spastic paraplegia 30.7 AP4S1 AP4M1 AP4E1 AP4B1
36 inherited metabolic disorder 30.6 TNF NOS3 MTHFR IL6 APOE
37 anxiety 30.6 TNF IL6 GAD1 BDNF APOE
38 exudative vitreoretinopathy 1 30.6 TNF NOS3 IL6 CXCL8 BDNF
39 respiratory failure 30.6 TNF MMP8 IL6 IL1B CXCL8
40 arteriovenous malformation 30.6 TNF IL6 APOE
41 lung disease 30.6 TNF TLR4 MMP8 IL6 IL1B CXCL8
42 overnutrition 30.6 TNF TLR4 NOS3 IL6 APOE
43 esophagitis 30.6 TNF IL6 IL1B CXCL8
44 osteonecrosis 30.6 TNF NOS3 MTHFR MMP8
45 placenta disease 30.5 TNF MTHFR IL6 IL1B CXCL8
46 myositis 30.5 TNF IL6 IL1B CXCL8
47 gingival overgrowth 30.5 TNF MMP8 IL6 CXCL8
48 nervous system disease 30.5 TNF IL6 IL1B BDNF APOE
49 measles 30.5 TNF TLR4 IL6 IL1B
50 mumps 30.4 TNF IL6 CXCL8

Comorbidity relations with Cerebral Palsy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Cerebral Palsy:



Diseases related to Cerebral Palsy

Symptoms & Phenotypes for Cerebral Palsy

UMLS symptoms related to Cerebral Palsy:


seizures, tremor, dystonia, back pain, pain, headache, abnormality of extrapyramidal motor function, involuntary movements, torticollis, muscle fibrillation, syncope, athetosis, asterixis, myokymia, chronic pain, sciatica, vertigo/dizziness, sleeplessness, muscle rigidity

MGI Mouse Phenotypes related to Cerebral Palsy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 AP4B1 AP4E1 AP4M1 APOE AUTS2 BDNF
2 growth/size/body region MP:0005378 10.18 AP4E1 APOE AUTS2 BDNF GAD1 IL1B
3 homeostasis/metabolism MP:0005376 10.18 AP4E1 AP4M1 APOE BDNF GAD1 IL1B
4 nervous system MP:0003631 10.07 AP4B1 AP4E1 APOE AUTS2 BDNF GAD1
5 adipose tissue MP:0005375 10.06 AP4E1 AP4M1 APOE AUTS2 IL6 NOS3
6 limbs/digits/tail MP:0005371 9.87 AP4E1 APOE GAD1 MTHFR NOS3 TLR4
7 no phenotypic analysis MP:0003012 9.7 ADD3 APOE AUTS2 BDNF GAD1 MTHFR
8 skeleton MP:0005390 9.7 AP4E1 APOE AUTS2 GAD1 IL1B IL6
9 vision/eye MP:0005391 9.28 AP4E1 APOE BDNF IL6 MTHFR NOS3

Drugs & Therapeutics for Cerebral Palsy

Drugs for Cerebral Palsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 293)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levodopa Approved Phase 4 59-92-7 6047
2
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Caffeine Approved Phase 4 58-08-2 2519
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
7
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
8
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
9
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
10
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
11
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
12
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
13
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
14 Dihydroxyphenylalanine Phase 4
15 Carbidopa, levodopa drug combination Phase 4
16 calcium heparin Phase 4
17 incobotulinumtoxinA Phase 4
18 Acidophilus Phase 4
19 Sunflower Phase 4
20 Citrate Phase 4
21 Central Nervous System Stimulants Phase 4
22 Chelating Agents Phase 4
23 Anticoagulants Phase 4
24 Phosphodiesterase Inhibitors Phase 4
25 Caffeine citrate Phase 4
26 Antipyretics Phase 4
27 Anesthetics Phase 4
28 Adrenergic Agonists Phase 4
29 Adrenergic alpha-2 Receptor Agonists Phase 4
30 Anesthetics, General Phase 4
31 Hypnotics and Sedatives Phase 4
32 Central Nervous System Depressants Phase 4
33 Adrenergic Agents Phase 4
34 Analgesics Phase 4
35 Anesthetics, Intravenous Phase 4
36 Analgesics, Non-Narcotic Phase 4
37 Anti-Inflammatory Agents, Non-Steroidal Phase 4
38 Cyclooxygenase Inhibitors Phase 4
39 Antirheumatic Agents Phase 4
40 Oxytocics Phase 4
41 Neuromuscular Agents Phase 4
42 Hormones Phase 4
43 Respiratory System Agents Phase 4
44 Anti-Inflammatory Agents Phase 4
45 Hormone Antagonists Phase 4
46 glucocorticoids Phase 4
47 Anti-Asthmatic Agents Phase 4
48 Betamethasone benzoate Phase 4
49 Betamethasone sodium phosphate Phase 4
50 Betamethasone Valerate Phase 4 2152-44-5

Interventional clinical trials:

(show top 50) (show all 969)
# Name Status NCT ID Phase Drugs
1 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
2 Effects of Functional Electrical Stimulation on Gait in Children With Hemiplegic and Diplegic Cerebral Palsy Unknown status NCT02462018 Phase 4
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
4 Changes of Gas Values in Cord Blood Versus Time and Temperature Unknown status NCT02785367 Phase 4
5 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
6 A Placebo Controlled, Cross-over, Double Blind, Randomized, Clinical Trial to Compare the Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
7 Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children Completed NCT00154830 Phase 4
8 Recurrent Crying Spells in Cerebral Palsy With Spastic Quadriparesis - A Crossover Study Completed NCT01955655 Phase 4 Baclofen
9 Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies. A Prospective, Randomized and Double-blinded Study Completed NCT00964639 Phase 4 Ropivacaine;Saline
10 Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of MEDITOXIN® in Children With Cerebral Palsy Completed NCT01256021 Phase 4 Botulinum Toxin Type A
11 A Randomized Controlled Trial on Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
12 SPREAD AND EFFECTIVENESS OF BOTULINUM NEUROTOXIN A IN SPASTIC EQUINUS IN CEREBRAL PALSY:SHORT-TERM STUDY Completed NCT01276015 Phase 4 Botulinum Toxin Type A
13 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
14 Efficacy of the Supplementation With a Symbiotic, a Prebiotic and a Probiotic to Produce a Beneficial Effect on the Intestinal Microbiota and on the Characteristics of Feces in Children With Cerebral Palsy (CP) and Chronic Constipation Completed NCT03117322 Phase 4
15 Effect of Magnesium Sulfate on the Incidence of Periventricular Leukomalacia in the Very Preterm Neonate Completed NCT00120588 Phase 4 magnesium
16 Magnetic Resonance Imaging and Neurodevelopmental Outcomes in Preterm Infants Following Administration of High-Dose Caffeine - A Pilot Study Completed NCT00809055 Phase 4 Caffeine citrate
17 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
18 Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy Recruiting NCT03648658 Phase 4 Paracetamol 120Mg/5mL Oral Suspension
19 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
20 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Active, not recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
21 Intrathecal (IT) Baclofen Drug Distribution Pilot Study Active, not recruiting NCT02903823 Phase 4 Baclofen bolus injection
22 Efficacy of a Peri-Operative Surgical-Site, Multimodal Drug Injection in Pediatric Patients With Cerebral Palsy Undergoing Hip Surgery: A Randomized Controlled Trial Not yet recruiting NCT04074265 Phase 4 Ropivacaine injection;normal saline
23 Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor: a Multicenter Randomized Controlled Trial Not yet recruiting NCT03991091 Phase 4 discontinuation of oxytocin administration;continuation of oxytocin administration
24 Improvement After Botulinum Toxin A Injections to the Upper Extremities in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
25 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Terminated NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
26 Randomized Trial on Efficacy and Safety of the Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth (ACG Trial) Terminated NCT00295464 Phase 4 Betamethasone sodium phos (drug)
27 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Withdrawn NCT01386255 Phase 4 Baclofen;placebo
28 Project:Intensive Habilitation (PIH) -a New Norwegian Multidisciplinary Program for Intensive Training for Children With Disabilities Unknown status NCT00202761 Phase 2, Phase 3
29 Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below Years. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01832454 Phase 2, Phase 3
30 Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial. Unknown status NCT01489904 Phase 2, Phase 3
31 Targeted Hip Progressive Resistance Training to Improve Single Leg Balance and Walking in Children With Cerebral Palsy Unknown status NCT01633736 Phase 3
32 Magnesium Prevention of Brain Injury in Preterm Infants Unknown status NCT00065949 Phase 3 magnesium sulfate
33 Modulation of Brain Plasticity After Perinatal Stroke: The PLASTIC CHAMPS Trial Unknown status NCT01189058 Phase 2, Phase 3
34 Effect of Early Application of Recombinant Human Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome Unknown status NCT03110341 Phase 3 Erythropoietin;Normal saline
35 A CLINICAL STUDY TO EVALUATE THE EFFICACY OF CAUSTICUM 200C IN THE TREATMENT OF PRIMARY ENURESIS Unknown status NCT02154152 Phase 3 Homoeopathic Medicine causticum 200c
36 Effectiveness of Vojta Therapy in Motor Development of Preterm Children Unknown status NCT01838278 Phase 3
37 Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy of "Botulax®" Versus "Botox®" in Children With Cerebral Palsy Completed NCT01787344 Phase 3 Botulinum Toxin Type A(Botox®);Botulinum toxin type A(Botulax®)
38 Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles. Assessment of Efficiency of Botulinum Toxin on Spasticity in Agonist and Antagonist Muscles Using Clinical Assessment and Gait Analysis in Cerebral Palsy Children: Rectus Femoris and Semitendinosus Completed NCT00133861 Phase 2, Phase 3 Botulinum toxin
39 Intrathecal Baclofen. Evaluation of a Therapy for Refractory Spasticity in Children With Cerebral Palsy Completed NCT00367068 Phase 3 baclofen, intrathecal
40 Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy: A Double-Blind, Randomized, Placebo-Controlled Trial Completed NCT00261131 Phase 3 Botulinum Toxin A
41 Relationship of Orthotics to Activity and Participation in Children With Cerebral Palsy Completed NCT01527162 Phase 3
42 Effectiveness of Intermittent Serial Casting on Spastic Wrist Flexion Deformity in Children With Cerebral Palsy Treated By Botulinum Toxin A Completed NCT03306212 Phase 3 Botulinum toxin A
43 A Phase III, Prospective, Multicentre, Open Label, Extension Study Assessing the Long Term Safety and Efficacy of Repeated Treatment With DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy Completed NCT01251380 Phase 3
44 Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Children With Cerebral Paralysis Completed NCT01929434 Phase 3
45 A Phase III, Multicentre, Double Blind, Prospective, Randomised, Placebo Controlled Study Assessing the Efficacy and Safety of DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy Completed NCT01249417 Phase 3 Placebo
46 Individualized Neurodevelopmental Treatment Completed NCT00922077 Phase 3
47 Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy Completed NCT02002884 Phase 3 IncobotulinumtoxinA (8 Units per kg body weight);IncobotulinumtoxinA (6 Units per kg body weight);IncobotulinumtoxinA (2 Units per kg body weight)
48 Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeomin® (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy Completed NCT01905683 Phase 3 IncobotulinumtoxinA (16-20 Units per kg body weight)
49 Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy Completed NCT01893411 Phase 3 IncobotulinumtoxinA (16 Units per kg body weight);IncobotulinumtoxinA (12 Units per kg body weight);IncobotulinumtoxinA (4 Units per kg body weight)
50 A Six-Month, Multi-Center, Open-Label Study to Assess the Safety and Efficacy of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Completed NCT00491894 Phase 3 Oral Glycopyrrolate Liquid

Search NIH Clinical Center for Cerebral Palsy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Baclofen
Dantrolene
Dantrolene Sodium

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cerebral Palsy cell therapies at LifeMap Discovery.

Genetic Tests for Cerebral Palsy

Genetic tests related to Cerebral Palsy:

# Genetic test Affiliating Genes
1 Cerebral Palsy 29

Anatomical Context for Cerebral Palsy

MalaCards organs/tissues related to Cerebral Palsy:

40
Brain, Testes, Bone, Heart, Spinal Cord, Lung, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cerebral Palsy:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Cerebral Palsy

Articles related to Cerebral Palsy:

(show top 50) (show all 21288)
# Title Authors PMID Year
1
Scoliosis in Non-Ambulatory Cerebral Palsy: Challenges and Management. 61 42
31713365 2019
2
Feasibility and safety of Robot Suit HAL treatment for adolescents and adults with cerebral palsy. 61 42
31337581 2019
3
Inflammatory markers in the saliva of cerebral palsy individuals with gingivitis after periodontal treatment. 61 42
31269113 2019
4
Identification of proteolipid protein 1 gene duplication by multiplex ligation-dependent probe amplification: first report of genetically confirmed family of Pelizaeus-Merzbacher disease in Korea. 54 61
18437021 2008
5
Reaching movements in childhood dystonia contain signal-dependent noise. 54 61
15996397 2005
6
The Xq22 inversion breakpoint interrupted a novel Ras-like GTPase gene in a patient with Duchenne muscular dystrophy and profound mental retardation. 54 61
12145744 2002
7
Amniotic fluid matrix metalloproteinase-8 and the development of cerebral palsy. 54 61
12235718 2002
8
Deleterious effects of IL-9-activated mast cells and neuroprotection by antihistamine drugs in the developing mouse brain. 54 61
11477207 2001
9
Late diagnosis of Lesch-Nyhan disease complicated with end-stage renal disease and tophi burst: a case report. 61
31985336 2020
10
A biomechanical comparison of initial sprint acceleration performance and technique in an elite athlete with cerebral palsy and able-bodied sprinters. 61
29768121 2020
11
Movement-based interventions for preschool-age children with, or at risk of, motor impairment: a systematic review. 61
31713851 2020
12
Improving Health-related Quality of Life for Patients With Nonambulatory Cerebral Palsy: Who Stands to Gain From Scoliosis Surgery? 61
31306277 2020
13
Is cerebral palsy a cause of death? 61
31904112 2020
14
Spasticity and pain in adults with cerebral palsy. 61
31602643 2020
15
Perspectives on cerebral palsy in Africa: Exploring the literature through the lens of the International Classification of Functioning, Disability and Health. 61
31856343 2020
16
Pain in adults with cerebral palsy: measuring the contribution of spasticity. 61
31696934 2020
17
Health-related quality of life, pain, and fatigue in young adults with cerebral palsy. 61
31777955 2020
18
A new tendon-lengthening technique using a tendon stripper for knee flexion contracture in a cerebral palsy patient. 61
32021014 2020
19
Impact of dosing schedule on uptake of neuroprotective magnesium sulfate. 61
30122071 2020
20
Anticholinergic medications for reducing drooling in children with developmental disability. 61
31495925 2020
21
Letter to the editor on "Relationship between changes in motor capacity and objectively measured motor performance in ambulatory children with spastic cerebral palsy". 61
32017230 2020
22
Trophic factors are essential for the survival of grafted oligodendrocyte progenitors and for neuroprotection after perinatal excitotoxicity. 61
31571668 2020
23
Prediction of Drug-Resistant Epilepsy in Children With Cerebral Palsy. 61
31684798 2020
24
How useful is the diagnosis of ataxic cerebral palsy? 61
32010973 2020
25
Cognitive functioning in children with cerebral palsy. 61
32010976 2020
26
Autonomy in participation in cerebral palsy from childhood to adulthood. 61
31578717 2020
27
Cerebral Palsy in Children With Congenital Zika Syndrome: A 2-Year Neurodevelopmental Follow-up. 61
31718421 2020
28
Musculoskeletal Imaging in Cerebral Palsy. 61
31760993 2020
29
Long-term effects of repeated botulinum neurotoxin A, bimanual training, and splinting in young children with cerebral palsy. 61
31225647 2020
30
Early Gross Motor Development Among Brazilian Children with Microcephaly Born Right After Zika Virus Infection Outbreak. 61
31453893 2020
31
Nutritional red flags in children with cerebral palsy. 61
30902487 2020
32
Botulinum Toxin in Children with Cerebral Palsy: An Update. 61
31486052 2020
33
The Expanding Role of Genetics in Cerebral Palsy. 61
31760988 2020
34
Optimizing Nutrition and Bone Health in Children with Cerebral Palsy. 61
31760992 2020
35
Technological Advancements in Cerebral Palsy Rehabilitation. 61
31760985 2020
36
Outcome Assessment and Function in Cerebral Palsy. 61
31760986 2020
37
Orthopedic Conditions in Adults with Cerebral Palsy. 61
31760990 2020
38
Surgical Tone Reduction in Cerebral Palsy. 61
31760996 2020
39
Comprehensive Care in Cerebral Palsy. 61
31760983 2020
40
Registry-based Research in Cerebral Palsy: The Cerebral Palsy Research Network. 61
31760991 2020
41
Status Dystonicus: A Rare Manifestation of Cerebral Palsy. 61
32036591 2020
42
Concurrent Validity and Reliability of an Inertial Measurement Unit for the Assessment of Craniocervical Range of Motion in Subjects with Cerebral Palsy. 61
32024117 2020
43
Prevalence of cerebral palsy with Gross Motor Function Classification System levels IV and V in children in Israel: a cross-cultural comparison. 61
31292758 2020
44
The relationship between neuroimaging and motor outcome in children with cerebral palsy: A systematic review-Part B diffusion imaging and tractography. 61
31901671 2020
45
Home Programme to Improve Hand Function for Children with Bilateral Cerebral Palsy: Beneficial but Challenging. 61
32037943 2020
46
Gait training facilitates push-off and improves gait symmetry in children with cerebral palsy. 61
31989957 2020
47
Flaunting our assets. Making the most of the Nordic registry goldmine: Cerebral palsy as an example. 61
30813853 2020
48
Acute and Chronic Pain in Children and Adolescents With Cerebral Palsy: Prevalence, Interference, and Management. 61
31521713 2020
49
Sex may influence motor phenotype in a novel rodent model of cerebral palsy. 61
31841677 2020
50
Anatomical and Functional Characterization in Children With Unilateral Cerebral Palsy: An Atlas-Based Analysis. 61
31983314 2020

Variations for Cerebral Palsy

ClinVar genetic disease variations for Cerebral Palsy:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ADD3 NM_016824.5(ADD3):c.1100G>A (p.Gly367Asp)SNV Pathogenic 242273 rs564185858 10:111882007-111882007 10:110122249-110122249
2 46;XX;t(1;5)(p31;q33)dnTranslocation Likely pathogenic 267832
3 46;XY;t(6;16)(p21.1;q21)dnTranslocation Uncertain significance 268038

Expression for Cerebral Palsy

Search GEO for disease gene expression data for Cerebral Palsy.

Pathways for Cerebral Palsy

Pathways related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 TNF IL6 IL1B GAD1 CXCL8
2
Show member pathways
12.8 TNF TLR4 IL6 IL1B CXCL8
3
Show member pathways
12.75 TNF TLR4 IL6 IL1B CXCL8
4
Show member pathways
12.69 TNF TLR4 IL6 IL1B BDNF
5
Show member pathways
12.37 AP4S1 AP4M1 AP4E1 AP4B1
6 12.36 TNF TLR4 IL1B CXCL8
7
Show member pathways
12.34 TNF MTHFR IL6 IL1B APOE
8
Show member pathways
12.31 TNF IL6 IL1B CXCL8
9
Show member pathways
12.31 TNF TLR4 IL6 IL1B CXCL8
10 12.29 TNF TLR4 IL6 IL1B CXCL8
11
Show member pathways
12.27 TNF IL6 IL1B CXCL8 BDNF
12
Show member pathways
12.25 TNF TLR4 IL6 CXCL8
13 12.23 TNF TLR4 IL6 IL1B
14 12.22 TNF TLR4 IL6 IL1B CXCL8
15
Show member pathways
12.21 TNF IL6 IL1B CXCL8
16
Show member pathways
12.15 TNF TLR4 IL6 IL1B CXCL8
17
Show member pathways
12.07 TNF TLR4 IL6 IL1B
18
Show member pathways
12.05 TNF TLR4 IL6 IL1B
19 12.03 AP4S1 AP4M1 AP4E1 AP4B1
20 11.99 TNF IL6 IL1B CXCL8
21 11.97 TNF TLR4 IL6 IL1B CXCL8
22 11.94 TNF PLP1 IL6 IL1B CXCL8 BDNF
23 11.92 TNF TLR4 IL1B CXCL8
24 11.86 TNF TLR4 IL6 IL1B CXCL8
25 11.83 TNF NOS3 IL6 IL1B CXCL8
26 11.8 TLR4 IL6 IL1B CXCL8
27 11.73 TNF IL6 IL1B
28 11.73 TNF IL6 IL1B BDNF
29 11.73 TNF TLR4 IL6 IL1B CXCL8
30
Show member pathways
11.66 TNF IL6 IL1B CXCL8
31 11.65 TNF IL6 IL1B CXCL8
32 11.6 TNF TLR4 IL6 IL1B CXCL8
33 11.52 TNF TLR4 IL1B
34 11.52 TNF IL6 IL1B CXCL8
35 11.46 TNF IL6 IL1B APOE
36 11.4 TNF IL6 IL1B
37 11.35 NOS3 IL6 CXCL8
38 11.32 TNF TLR4 IL6 IL1B
39 11.31 TNF IL6 IL1B
40 11.31 TNF TLR4 IL6 IL1B CXCL8
41 11.26 TNF IL6 IL1B
42 11.2 TNF MTHFR IL6 IL1B
43 11.18 TNF TLR4 IL6 IL1B CXCL8 BDNF
44 11.05 TNF IL6 CXCL8
45 11.05 TNF TLR4 IL6 IL1B CXCL8

GO Terms for Cerebral Palsy

Cellular components related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 trans-Golgi network membrane GO:0032588 9.46 AP4S1 AP4M1 AP4E1 AP4B1
2 clathrin adaptor complex GO:0030131 9.26 AP4M1 AP4B1
3 endosome lumen GO:0031904 9.26 AP4S1 AP4M1 AP4E1 AP4B1
4 AP-4 adaptor complex GO:0030124 8.92 AP4S1 AP4M1 AP4E1 AP4B1

Biological processes related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.04 TNF TLR4 IL6 IL1B CXCL8
2 inflammatory response GO:0006954 9.97 TNF TLR4 PLP1 IL6 IL1B CXCL8
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.9 TNF TLR4 IL6 IL1B
4 positive regulation of JNK cascade GO:0046330 9.84 TNF TLR4 MMP8 IL1B
5 positive regulation of inflammatory response GO:0050729 9.83 TNF TLR4 IL1B
6 protein localization GO:0008104 9.83 AP4S1 AP4M1 AP4E1 AP4B1
7 cellular response to lipopolysaccharide GO:0071222 9.83 TNF TLR4 IL6 IL1B CXCL8
8 positive regulation of gene expression GO:0010628 9.8 TNF TLR4 PLP1 NOS3 MMP8 IL6
9 positive regulation of interferon-gamma production GO:0032729 9.78 TNF TLR4 IL1B
10 positive regulation of interleukin-6 secretion GO:2000778 9.75 TNF TLR4 IL1B
11 negative regulation of neurogenesis GO:0050768 9.73 TNF IL6 IL1B
12 positive regulation of interleukin-8 production GO:0032757 9.72 TNF TLR4 IL1B
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.71 TNF TLR4 MMP8 IL1B
14 positive regulation of chemokine production GO:0032722 9.69 TNF TLR4 IL6
15 protein targeting GO:0006605 9.67 AP4S1 AP4M1 AP4E1 AP4B1
16 locomotory exploration behavior GO:0035641 9.65 GAD1 APOE
17 positive regulation of glial cell proliferation GO:0060252 9.65 TNF IL6 IL1B
18 positive regulation of chemokine biosynthetic process GO:0045080 9.64 TNF IL1B
19 regulation of neuroinflammatory response GO:0150077 9.63 MMP8 IL6
20 negative regulation of lipid storage GO:0010888 9.63 TNF IL6
21 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 TNF IL1B APOE
22 negative regulation of platelet activation GO:0010544 9.62 NOS3 APOE
23 regulation of establishment of endothelial barrier GO:1903140 9.62 TNF IL1B
24 positive regulation of nitric oxide biosynthetic process GO:0045429 9.62 TNF TLR4 MMP8 IL1B
25 positive regulation of fever generation GO:0031622 9.61 TNF IL1B
26 regulation of microglial cell activation GO:1903978 9.59 MMP8 IL6
27 sequestering of triglyceride GO:0030730 9.58 TNF IL1B
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.57 TNF IL1B
29 lipopolysaccharide-mediated signaling pathway GO:0031663 9.46 TNF TLR4 NOS3 IL1B
30 positive regulation of interleukin-6 production GO:0032755 9.35 TNF TLR4 MMP8 IL6 IL1B
31 positive regulation of neuroinflammatory response GO:0150078 8.92 TNF MMP8 IL6 IL1B

Molecular functions related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF IL6 IL1B CXCL8

Sources for Cerebral Palsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....